Clene (FRA:84C) FCF Yield % : -54.61 (As of May. 06, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Clene FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Clene's Trailing 12-Month Free Cash Flow is €-28.31 Mil, and Market Cap is €52.06 Mil. Therefore, Clene's FCF Yield % for today is -54.61%.

The historical rank and industry rank for Clene's FCF Yield % or its related term are showing as below:

FRA:84C' s FCF Yield % Range Over the Past 10 Years
Min: -90.43 Med: -25.74 Max: -2.28
Current: -54.61

During the past 5 years, the highest FCF Yield % of Clene was -2.28%. The lowest was -90.43%. And the median was -25.74%.

FRA:84C's FCF Yield % is ranked worse than
76.46% of 1555 companies
in the Biotechnology industry
Industry Median: -14.32 vs FRA:84C: -54.61

Clene's FCF Margin % for the quarter that ended in Dec. 2023 was -4,241.03%.

Clene FCF Yield % Historical Data

The historical data trend for Clene's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clene FCF Yield % Chart

Clene Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Yield %

-14.76

-63.41

-87.82

Clene Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Yield %	Get a 7-Day Free Trial												-54.05	-44.17	-24.63	-43.01	-83.09

Competitive Comparison of Clene's FCF Yield %

For the Biotechnology subindustry, Clene's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clene's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clene's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Clene's FCF Yield % falls into.

Clene FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Clene's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-27.97	/	31.848904
	=	-87.82%

Clene's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-6.616	*	4	/	31.848904
	=	-83.09%

Clene FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Clene FCF Yield % Related Terms

Thank you for viewing the detailed overview of Clene's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Clene (FRA:84C) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clene Inc (FRA:84C) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

CLNN:USA

Address

6550 South Millrock Drive, Suite G50, Salt Lake City, UT, USA, 84121

Website

https://www.clene.com

Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. Its reportable segments: (1) the development and commercialization of novel clean-surfaced nanotechnology therapeutics (Drugs, and (2) the development and commercialization of dietary supplements (Supplements).

Clene (FRA:84C) Headlines

No Headlines